^
    Back
    Association details:
    Biomarker:TARDBP-BRAF fusion
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    LY3009120 (pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cell Rep
    Title:

    Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses

    Excerpt:
    We used a xenograft model of the most resistant cell line, M368, to assess the effectiveness of combination treatment with trametinib (0.3 mg/kg oral gavage BID) and LY3009120 (15 mg/kg oral gavage BID) in vivo….While monotherapy with trametinib or LY3009120 significantly decreased tumor growth, the combination treatment resulted in a more profound suppression of tumor growth...
    DOI:
    10.1016/j.celrep.2019.09.009